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Aberrant activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) 3 has been
implicated in cell proliferation andsurvival ofmany cancers including head and neck squamouscell carcinoma (HNSCC).
AZD1480, an orally active pharmacologic inhibitor of JAK1/JAK2, has been tested in several cancer models. In the
present study, the in vitro and in vivo effects of AZD1480 were evaluated in HNSCC preclinical models to test the
potential useof JAK kinase inhibition for HNSCC therapy. AZD1480 treatment decreasedHNSCCproliferation inHNSCC
cell lines with half maximal effective concentration (EC50) values ranging from 0.9 to 4 μM in conjunction with reduction
of pSTAT3Tyr705 expression. In vivo antitumor efficacy of AZD1480wasdemonstrated in patient-derived xenograft (PDX)
models derived from two independent HNSCC tumors. Oral administration of AZD1480 reduced tumor growth in
conjunction with decreased pSTAT3Tyr705 expression that was observed in both PDX models. These findings suggest
that the JAK1/2 inhibitors abrogate STAT3 signaling and may be effective in HNSCC treatment approaches.
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Activation of the Janus kinase/signal transducer and activator of
transcription (JAK/STAT) pathway has been detected in many
human cancers [1–3]. JAKs are a family of cytoplasmic tyrosine
kinases, comprised of four members—JAK1, JAK2, JAK3, and Tyk2
[4]. JAK activation occurs upon binding of a ligand to cell surface
receptors, which phosphorylates tyrosine residues on the receptor and
creates sites for interaction with proteins that contain phosphotyr-
osine binding SH2 domains [4]. The STATs are a family of
downstream transcription factors of JAKs and other kinases and
include STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and
STAT6 [5]. STATs contain a conserved tyrosine residue near the
C-terminus that is phosphorylated by JAKs, leading to the formation
of homo-STAT or hetero-STAT dimers, tyrosine phosphorylation,
and subsequent nuclear translocation [6]. In the nucleus, STATs
serve as transcription factors initiating the transcription of down-
stream target genes [7]. Abnormalities of the JAK/STAT pathway
contribute directly to cellular transformation [8], increased cell
proliferation, survival, angiogenesis, and immune system evasion [7].Cumulative evidence implicates STAT3 in cancer development
and progression. Elevated STAT3 activity has been associated with
increased morbidity and mortality in several cancers including
multiple myeloma, leukemia, lymphoma, and breast and head and
neck squamous cell carcinoma (HNSCC) [9]. We recently reported
that the JAK/STAT pathway is rarely mutated in HNSCC in contrast
to activating JAK mutations that characterize hematopoietic
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[10,11]. Several approaches have been used to target STAT3 for
cancer therapy [7]. These include peptidomimetics, aptamers,
antisense oligonucleotides, G quartets, STAT3 decoys, dominant-
negative mutants of STAT3, and small molecule tyrosine kinase
inhibitors [12,13]. To date, a decoy oligonucleotide is the only
STAT3 selective inhibitor, which has demonstrated biologic activity
in HNSCC patients in a phase 0 clinical trial [14]. However,
challenges in drug delivery have limited the clinical translation of
transcription factor decoys [14].
JAK2 activating mutations and chromosomal translocations have
identified JAK2 as a target for the treatment ofmyelofibrosis andmay be a
molecular target in several other cancers [4,9]. Given the paucity of small
molecule STAT3-selective therapies, JAK inhibitors can be used to target
STAT3 activation for cancer treatment. AZD1480 is a potent,
ATP-competitive small-molecule inhibitor of JAK2 kinase [15].
AZD1480 demonstrated antitumor activity in several cancer models.
In multiple myeloma cells, AZD1480 abrogated Interleukin -6 (IL-6)–
induced activation of JAK2 and tyrosine phosphorylation of STAT3 [16].
In glioblastoma, AZD1480 suppressed STAT3 activation in vitro and
inhibited the growth of xenograft tumors in vivo[17]. In the present
study, the in vitro and in vivo efficacy of AZD1480 was evaluated in
HNSCC preclinical models for the first time. In vitro, AZD1480
decreased HNSCC cell proliferation as well as STAT3 phosphorylation.
In vivo, AZD1480 significantly slowed tumor growth in heterotopic
xenograft tumor models derived from two HNSCC patient tumors in
conjunction with downmodulation of pSTAT3 expression. These results
suggest that JAK kinase inhibition may be a promising approach to target
STAT3 signaling pathways in solid tumors, including HNSCC, which
lack genetic JAK/STAT alterations.
Materials and Methods
Cell Lines and Reagents
HNSCC cell lines UMSCC-1, UM-22B, UM-22A, Cal33,
PCI-15B, HN5, OSC19, PCI-52, and 686LN were genotypically
validated using the AmpFlSTR Profiler Plus kit from PE Biosystems
(Foster City, CA) according to the manufacturer's instructions.
AZD1480 was obtained from Astra Zeneca, Waltham, MA.
Cell Culture
HNSCC cell lines UMSCC-1, UM-22B, and UM-22A
(a generous gift from Dr Thomas E. Carey, University of Michigan),
Cal33 (a kind gift from Jean Louis Fischel, Centre Antoine
Lacassagne, Nice, France), PCI-52 and PCI-15B (created at the
University of Pittsburgh), and HN5 and OSC19 were cultured in
Dulbecco's modified Eagle's medium (Mediatech, Inc, Herndon,
VA) containing 10% heat-inactivated FBS at 37°C with 5% CO2.
686 LN (a kind gift from Georgia Chen, University of Emory,
Atlanta, GA) was maintained in Dulbecco's modified Eagle's
medium/F12 media (1:1) from Gibco (Carlsbad, CA) containing
10% heat-inactivated FBS (ISC BioExpress, Kaysville, UT).
Immunoblot Analysis
A panel of HNSCC cell lines including UMSCC-1, UM-22B,
UM-22A, Cal33, PCI-15B, HN5, OSC19, PCI-52, and 686LN was
seeded in 10-cm plates (1 × 106 cells), and after 24 hours, cells were
harvested to obtain cell lysates. Forty micrograms of protein/lane was
separated by 10% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and probed with rabbit anti–phospho-JAK1 andJAK2 polyclonal antibodies (Millipore, Billerica, MA), rabbit anti–
phospho-STAT3 monoclonal antibody, and STAT3 polyclonal
antibodies (Cell Signaling Technology, Inc, Danvers, MA). β-Tubulin
(Abcam, Cambridge, MA) was used as a loading control.
The Cancer Genome Atlas Analyses
mRNA expression data, mutation data, and gene copy number
data on 279 HNSCC tumors were downloaded from The Cancer
Genome Atlas (TCGA) Data Portal using R version 3.02. Tumors
with JAK copy number alteration were compared to tumors without
JAK copy number alteration using an unpaired t test with Welch’s
correlation in Graphpad Prism 6.
Dose-Response Studies
HNSCC cell lines were treated with varying concentrations of
AZD1480 for 72 hours. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assays were performed to determine
percent cell viability.
siRNA Transfection
JAK2 siRNA was obtained from Dharmacon (Lafayette, CO),
whereas the control siRNA was obtained from Thermo Scientific
(Pittsburgh, PA). siRNA transfection was performed using Lipofec-
tamine RNAi/MAX from Invitrogen (Grand Island, NY) following
the manufacturer’s instructions with a final siRNA concentration of
5 pmol/well. Protein was extracted 48 and 72 hours after transfection
and immunoblotted for pSTAT3Tyr705 and total STAT3. β-Tubulin
was used as a loading control. Cell proliferation assays were performed
on days 1, 3, and 6 after transfection.
Dose-Dependent Effect of AZD1480 in HNSCC Cell Lines
HNSCC cell lines (UMSCC-1, Cal33, and HN5) were plated, and
after 24 hours of plating, cells were serum starved for an additional 24
hours and treated with increasing concentrations of AZD1480.
Fifteen minutes before the end of 24 hours, cells were stimulated
with IL-6 (50 ng/ml) cells. At the end of the 24-hour treatment time,
cells were harvested to obtain cell lysates. Forty micrograms of
protein/lane was subjected to electrophoresis and immunoblotted for
pSTAT3Tyr705 and total STAT3, Bcl-XL, and cyclin D1. β-Tubulin
was used as a loading control.
Dose-Dependent Effect of AZD1480 on pSTAT3Tyr705 in
HNSCC Cell Lines
HNSCC cell lines UMSCC-1 and Cal33 were plated, and after 24
hours of plating, cells were treated with increasing concentrations of
AZD1480. At the end of the 24-hour treatment time, cells were
harvested to obtain cell lysates. Forty micrograms of protein/lane was
subjected to electrophoresis and immunoblotted for pSTAT3Tyr705
and STAT3. β-Tubulin was used as a loading control.
Dose-Dependent Effect of AZD1480 on pSTAT5Tyr694 in
Cal33 Cell Lines
Cal33 cell lines were plated, and after 24 hours of plating, cells
were serum starved for an additional 24 hours and treated with
increasing concentrations of AZD1480. Fifteen minutes before the
end of 24 hours, cells were stimulated with IL-6 (50 ng/ml) cells. At
the end of the 24-hour treatment time, cells were harvested to obtain
cell lysates. Forty micrograms of protein/lane was subjected to
electrophoresis and immunoblotted for pSTAT5Tyr694. β-Tubulin
was used as a loading control.
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Xenograft Studies
Human tumors were obtained under the auspices of an
Institutional Review Board (IRB)-approved protocol with informed
consent. The tumor tissues were processed for Western blot analyses
as described previously [18] to look at the expression of pJAK1,
pJAK2, JAK1, and JAK2. β-Tubulin was used as a loading control.
For the in vivo experiment, nonobese diabetic/severe combined
immunodeficiency (NOD SCID) gamma mice (4-6 weeks old; 20 g;
The Jackson Laboratory, Bar Harbor, Maine) were implanted with
tumors subcutaneously from two different HNSCC patients. Before
implantation, each mouse was anesthetized using isoflurane, and the
area for the incision was prepared using iodine and alcohol
preparation pads. A half centimeter incision or smaller was made,
and a 25-mg tumor section was placed under the skin in both the
right and left flanks. The wound was closed with Vetbond Tissue
Adhesive, and a single injection of ketoprofen was given intramuscu-
larly at a dose of 5 mg/kg. The animal was monitored until it was fully
mobile and had recovered all normal functions. Once the tumors were
palpable, mice were randomized and treated with AZD1480 or saline
as a vehicle. Four groups (two groups of five mice with two tumors on
each side from one patient and another two groups of five mice with
two tumors on each side from a second patient) received either
AZD1480 at a dose of 30 mg/kg or saline through oral gavage, twice
daily, and at the end of the treatment period, tumors were harvested
and lysates were collected for determination of pSTAT3Tyr705 and
STAT3 expression. Animal care was in strict compliance with
institutional guidelines established by the University of Pittsburgh,
the Guide for the Care and Use of Laboratory Animals (National
Academy of Sciences, 1996), and the Association for Assessment and
Accreditation of Laboratory Animal Care International. In addition,
lysates from HNSCC patient tumors were collected and probed for
expression of pJAK1, pJAK2, JAK1, and JAK2 expression.
Statistical Analyses
Statistical analyses of the in vitro cell line comparison studies as
well as the in vivo antitumor efficacy of AZD1480 on tumor volume
measurements on the last day of the xenograft experiment were
compared by testing the difference, with a two-tailed Wilcoxon test.
Results
HNSCC Cell Lines Express Variable Levels of Phospho-JAK1,
Phospho-JAK2, Phospho-JAK3, and Phospho-STAT3 Expression
Levels and JAK2 Copy Number Correlates with JAK2 mRNA
Expression in HNSCC Tumors
STAT3 activation has been studied in HNSCC downstream of
several receptor and non-receptor kinases. The precise role of JAK
kinases in HNSCC is incompletely understood. To determine the
relative expression levels of total and phosphorylated forms of JAK1,
JAK2, JAK3, and STAT3 in HNSCC cells, a panel of genotypically
validated HNSCC cell lines including UMSCC-1, UM-22B,
UM-22A, Cal33, PCI-15B, HN5, OSC19, PCI-52, and 686LN
was evaluated for pJAK1, JAK1, pJAK2, JAK2, pJAK3, JAK3,
pSTAT3Tyr705, and STAT3 protein expression levels. As shown in
Figure 1A, HNSCC cells demonstrated varying levels of pJAK1,
pJAK2, pJAK3, and pSTAT3 in the cell lines tested. TCGA HNSCC
samples were grouped according to their copy number alteration
status. A copy number alteration of −2 is considered a homozygous
deletion, −1 is a heterozygous deletion, 0 is no copy numberalteration, 1 is a gain, and 2 is high level amplification. The copy
number data sets were generated by the GISTIC or RAE copy
number analysis algorithms in the TCGA portal. Both algorithms
identify significantly altered regions of amplification or deletion.
Although inconsistencies between copy number alteration (CNA)
and gene expression profiles have been previously found in other
cancer types [19], we compared RNAseq values of HNSCC tumors
with altered gene copy number for the JAK family of proteins to
HNSCC tumors without copy number change. As shown in
Figure 1B, there is a significant correlation only between heterozygous
deletion of JAK1 and JAK1 mRNA expression (CNA = −1, P b
.0001). JAK1 is not commonly upregulated, and when it is, there is
no apparent correlation between copy number alteration and mRNA
expression (P = .1438). As shown in Figure 1C, JAK2 is commonly
upregulated, and there is a significant correlation between copy
number alteration and mRNA expression (CNA = 1, P = .0168;
CNA = 2, P = .0069). There are also significant correlations between
copy number losses and mRNA expression (CNA = −1, P b .0001;
CNA = −2, P b .0001). We also compared RNAseq values of
HNSCC tumors with JAK2 copy number alteration status of 1 to
that of HNSCC tumors with copy number alteration status of 2 (P =
.0307). Similarly to our JAK1 findings, JAK3 is rarely upregulated
and high-level amplification is not significantly associated with
increased JAK3 mRNA expression (Figure 1D; P = .1070).
AZD1480 Inhibits HNSCC Cell Line Proliferation In Vitro
AZD1480 has been reported to inhibit the proliferation of some
solid tumor cell lines, whereas many others are clearly resistant to
AZD1480 with concentration that inhibits growth by 50% (GI50)
values N30 μM [15]. Dose-response experiments were performed in a
panel of HNSCC cell lines to determine the relative sensitivity of
HNSCC preclinical models. UMSCC-1, UM-22B, UM-22A, Cal33,
PCI-15B, HN5, OSC19, PCI-52, and 686LN cells were treated with
a range of doses of AZD1480 for 72 hours, and MTT assays were
performed to assess cell viability. The half maximal effective
concentration (EC50) values of all the cell lines tested ranged from
0.9 to 3.8 μM, suggesting that the majority of HNSCC cells are
sensitive to JAK1/2 inhibition (Table 1).
JAK2 Down-Regulation Attenuates HNSCC Proliferation
We next explored whether selective inhibition of JAK2 attenuated
proliferation of HNSCC cells. UMSCC-1 and HN5 cells when
transfected with JAK2 siRNA demonstrated knockdown of JAK2
expression after 48 and 72 hours, and proliferation of these HNSCC
cells was reduced on treatment of the cells with JAK2 siRNA
compared with control siRNA (Figure 2, A and B).
Dose-Dependent Effect of AZD1480 on pSTAT3Tyr705 Protein
Expression in HNSCC Cell Lines
AZD1480 targets both JAK1 and JAK2 kinases. STAT3 is
activated downstream of several kinases including JAKs. While there is
little evidence to date to support a critical function of JAKs in HNSCC,
cumulative evidence implicates STAT3 activation in HNSCC
progression [2]. To determine the effect of AZD1480 on pSTAT3
expression, UMSCC-1, HN5, Cal33, 686LN, or PCI-15B cells were
treated with increasing concentrations of AZD1480 for 24 hours,
followed by immunoblot analysis for pSTAT3Tyr705 and STAT3.
AZD1480 abrogated IL-6–induced up-regulation of pSTAT3Tyr705 in
a dose-dependent manner in UMSCC-1, HN5, and Cal33 cells
(Figure 3). Similar effects were seen on pSTAT3 expression in the
Figure 1. (A) HNSCC cell lines express varying levels of pJAK1, pJAK2, and pSTAT3. HNSCC cell lines (OSC19, 686LN, HN5, UMSCC-1,
UM-22B, PCI-15B, PCI-52, Cal33, and UM-22A) were seeded in 10-cm plates (1 × 106 cells), and after 24 hours, cells were harvested to
obtain cell lysates. Forty micrograms of protein/lane was subjected to electrophoresis and immunoblotted for pJAK1, pJAK2, pJAK3, and
pSTAT3Tyr705. β-Tubulin was used as a loading control. The numbers below the bands are a quantitative representation of pJAK1/
β-tubulin, pJAK2/β-tubulin, pJAK3/β-tubulin, and pSTAT3Tyr705/β-tubulin in HNSCC cell lines from three independent experiments. (B)
Association between JAK2mRNA expression and JAK2 copy number alteration in HNSCC tumors determined by GISTIC or RAE algorithm
in the TCGA portal (*P b .0001; **P b .0001; ***P= .0168; ****P= .0069; *****P= .0307). P values were determined by unpaired t test
with Welch’s correlation. (C) Association between JAK1 mRNA expression and JAK1 copy number alteration in HNSCC tumors
determined by GISTIC or RAE algorithm in the TCGA portal (*P b .0001). P value was determined by unpaired t test with Welch’s
correlation. (D) Association between JAK3 mRNA expression and JAK3 copy number alteration in HNSCC tumors determined by GISTIC
or RAE algorithm in the TCGA portal (*P b .0001). P values were determined by unpaired t test with Welch’s correlation.
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Table 1. EC50 Values for AZD1480 in HNSCC Cell Lines. HN5, Cal33, UM-22B, 686LN,
UMSCC-1, UM-22A, OSC19, PCI-52, and PCI-15B Cells Were Treated with a Range of
Concentrations of AZD1480 for 72 Hours. MTT Assays Were Then Performed and EC50 Values
were Calculated. The Experiment was Performed Three Times with Similar Results. Results are
Mean ± SD for All Three Experiments Combined
HNSCC Cell Line EC50 (μM)
HN5 3.81 ± 1.99
Cal33 3.37 ± 0.75
UM-22B 2.66 ± 0.24
686LN 2.05 ± 1.33
UM SCC-1 1.67 ± 0.42
UM-22A 1.32 ± 0.39
OSC19 1.26 ± 0.20
PCI-52 1.00 ± 0.09
PCI-15B 0.99 ± 1.74
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treatment also abrogated pSTAT3 expression in these cells (Figure S2).
In addition to STAT3, STAT5 is also constitutively activated in
HNSCC cells [20]. To determine the effect of AZD1480 on
pSTAT5 expression, Cal33 cells were treated with increasing
concentrations of AZD1480 for 24 hours, followed by immunoblot
analysis for pSTAT5Tyr694. Similar to its effects on pSTAT3,
AZD1480 abrogated IL-6–induced up-regulation of pSTAT5Tyr694
in a dose-dependent manner in Cal33 cells (Figure S3).
AZD1480 Inhibits Growth and STAT3 Signaling In Vivo of
HNSCC Patient-Derived Xenografts
Immortalized cell lines bear limited resemblance to human tumors.
To determine the antitumor effects of AZD1480, we generated
heterotopic tumorgraft models of primary HNSCC tumors and
assessed the consequences of AZD1480 treatment in these models.
Both patient-derived xenograft (PDX) models were derived fromFigure 2. Proliferation of HNSCC cells upon knockdown of JAK2 by JA
siRNA or control siRNA, and after 48 and 72 hours, cells were harvest
upon JAK2 knockdown after days 1, 3, and 6. Results are from threeHuman papillomavirus (HPV)-negative oral cavity tumors. As shown
in Figure 4A, AZD1480 administration effectively abrogated the
growth of both HNSCC tumorgrafts (30 mg/kg, administered twice
daily through oral gavage) compared with saline (vehicle) treatment.
At the end of treatment, tumors derived from patient 1 and treated
with AZD1480 demonstrated a significant decrease in tumor volume
(P = .0037) compared to the group treated with vehicle control.
Tumors derived from patient 2, treated with AZD1480, demon-
strated a decrease in tumor volume compared to the group treated
with vehicle, although the difference did not reach statistical
significance (P = .066). At the end of treatment, the tumors were
harvested 3.5 hours after the last treatment and evaluated for pSTAT3
expression through immunoblot analysis (Figure 4B). Five of the nine
tumors from patient 1 treated with AZD1480 were too small to be
harvested for immunoblot analysis. Tumors from both patient 1 and
patient 2 treated with AZD1480 demonstrated a significant decrease
in pSTAT3Tyr705 expression compared to the tumors treated with
vehicle alone (P = .003 and P = .0006, respectively; Figure 4C).
Discussion
In the present study, the orally bioavailable JAK1/2 inhibitor
AZD1480 was evaluated in HNSCC preclinical models to determine
its antitumor efficacy. Evaluation of pJAK1, pJAK2, pJAK3, and
pSTAT3 in a panel of nine immortalized HNSCC cell lines
demonstrated variable endogenous expression levels of these proteins.
Although JAK1 mutations have been detected in breast and gastric
carcinomas [21], in TCGA, JAK1/2 mutations have been reported in
a very small head and neck cancer patient population. Additionally,
significant correlation of CNA and gene expression profiles in the
TCGA HNSCC cohort is only seen for JAK2 and there is no evident
correlation between CNA and gene expression for JAK1 or JAK3 in
HNSCC. Discrepancies between CNA and gene expression levelsK2 siRNA. (A) UMSCC-1 and HN5 cells were transfected with JAK2
ed for JAK2 expression. (B) Further cell proliferation was monitored
separate experiments.
Figure 3. Effect of AZD1480 on pSTAT3Tyr705 expression in HNSCC cell lines. UMSCC-1, HH5, Cal33, and UM-22A cells were treated with
increasing concentrations of AZD1480. After 24 hours of treatment, cells were stimulated with IL-6 (50 ng/ml) for the last 15 minutes. At
the end of the treatment, cells were harvested to obtain cell lysates. Forty micrograms of protein/lane was subjected to electrophoresis
and immunoblotted for pSTAT3Tyr705 and total STAT3. β-Tubulin was used as a loading control. The experiment was performed three
times with similar results.
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copy number losses did not necessarily correlate with gene expression
levels [19] and in oral squamous cell carcinoma (OSCC) where CNA
could be attributed to only 31% of gene expression differences
detected [22]. The exact mechanism for correlation of CNA and gene
expression is unknown, and other factors, such as DNA methylation,
or histone acetylation, methylation, and phosphorylation, may
contribute. In vitro and in vivo studies with AZD1480 in HNSCC
cell lines and PDXs demonstrated antiproliferative and antitumor
efficacy in conjunction with inhibition of STAT3 phosphorylation.
HNSCC cell lines treated with AZD1480 demonstrated EC50 values
in the nanomolar or submicromolar range that did not correlate with
endogenous pSTAT3 expression levels. Further, we also examined the
effect of JAK2 siRNA on HNSCC cell proliferation and we did not
find any correlation between sensitivity to JAK2 siRNA and response
to AZD1480. Biochemical evaluation of AZD1480 in HNSCC cell
lines showed dose-dependent decreases in pSTAT3 expression with
increasing AZD1480 concentrations. Evaluation of in vivo antitu-
mor efficacy in PDXs demonstrated abrogation of tumor volumes in
conjunction with decreases in pSTAT3 expression in the tumors
from mice treated with AZD1480 compared to vehicle control–
treated animals. The responses of HNSCC PDXs to AZD1480
treatment underscores the heterogeneous responses likely to be
observed in the clinic and emphasizes the need for predictive
biomarkers to identify individuals who are most likely to benefit from
this treatment strategy.
The contribution of persistent STAT3 activation to tumor
progression, drug resistance, cell migration and invasion, angiogen-
esis, and metastasis of cancer has identified STAT3 as a therapeutic
target in preclinical models of most malignancies [23,24]. Although a
large number of STAT3 inhibitors have been reported to date, there is
a paucity of selective small molecule STAT3 targeting agents under
clinical development [25]. Given the challenges associated withdeveloping small molecule inhibitors that directly inhibit the STAT3
transcription factor, targeting upstream activating kinases such as
JAKs offers a pharmaceutically viable alternative to block STAT3
signaling. Several JAK1/2 inhibitors have been developed following
the discovery of the JAK2 mutation (JAK2V617F) in myeloprolif-
erative disorders [26]. A number of these JAK inhibitors have been
assessed for their effectiveness in a variety of preclinical cancer models.
A natural compound screen identified JSI-124 (cucurbitacin I), which
is very effective at suppressing the levels of tyrosine-phosphorylated
STAT3 and JAK2 but is unable to directly inhibit Src, JAK1, or JAK2
kinase activities in vitro, indicating a lack of clarity about the precise
target of this compound. JSI-124 suppressed proliferation, induced
DNA fragmentation, poly(ADP-ribose) polymerase cleavage, and
caspase-3 activation in a dose-dependent manner in OSCC cell lines.
JSI-124 also decreased expression of pSTAT3 expression as well as
survivin, a downstream target of STAT3 signaling pathway. However,
the in vivo antitumor efficacy of JSI-124 in OSCC has not been
reported [27]. In nasopharyngeal cancer, administration of JSI-124 in
nude mice before tumor cell inoculation suppressed in vivo tumor
formation [28]. WP1066, a JAK2 inhibitor, demonstrated antitumor
effects mediated, at least in part, by suppression of JAK2-STAT3
signaling in preclinical HNSCC models [3]. FLLL32, a novel small
molecule inhibitor derived from curcumin, induced sensitized
HNSCC cells to cisplatin in vitro[29].
In the absence of preclinical data on the effects of JAK1/2
inhibitors in HNSCC, we tested AZD1480 in HNSCC models to
determine its antitumor properties. AZD1480, a pharmacologic
inhibitor of JAK1/2, has been used as a therapeutic strategy to target
STAT3 signaling in several cancers including glioblastoma [17], skin
[16], and lymphoma [30], among others. The results of our study and
others [31,32] demonstrate that AZD1480 affects the expression of
pSTAT3 and pSTAT5. Others have reported that in addition to
effects on pSTAT3, AZD1480 downregulates expression of STAT3
Figure 4. AZD1480 suppresses growth and expression of pSTAT3Tyr705 target genes in HNSCC patient-derived heterotopic tumorgrafts.
(A) HNSCC tumors from two individual patients were inoculated subcutaneously in the right and left flanks of NOD SCID gamma mice.
Following the development of palpable tumors, mice were randomized and AZD1480 at a dose of 30 mg/kg was administered twice daily
through oral gavage. Tumor volume measurements were obtained three times a week and measured to days 15 and 13 and are graphed.
The nonparametric Wilcox Mann-Whitney test was used for tumor volume on day 15 to determine significance. (B) At the end of
treatment (day 13 for patient 1 tumors and day 15 for patient 2 tumors), tumors were harvested, and whole-cell lysates were prepared and
subjected to immunoblot analysis for pSTAT3Tyr705 and STAT3. β-tubulin was used to assess protein loading. (C) The bar graph is a
quantitative representation of the ratio of pSTAT3Tyr705/β-tubulin (P = .003, patient 1 and P = .066, patient 2).
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[16,33]. Knockdown of JAK2 using siRNA from our studies and
others [32] is associated with reduced expression of pSTAT3. Inpapillary thyroid carcinoma and medullary thyroid carcinoma,
AZD1480 demonstrated reduced phospho-Y1062 receptor tyrosine
kinase for members of the glial cell line-derived neurotrophic factor
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(mTOR) effector phospho-S6, while JAK1/2 down-regulation by
siRNA did not affect cell growth nor RET and S6 activation [34]. In
the present study, a lack of significant correlation between
biochemical target inhibition and EC50 values suggests that
expression levels of target(s) in the tumor do not predict sensitivity
to AZD1480 and the capacity to predict therapy outcome does not
merely depend on the expression of these STAT3 pathway proteins in
tumor cells. PDXs are emerging as potentially more relevant
preclinical models in many cancers including HNSCC [35,36].
Although they require a significant investment of resources and a
commitment to transfer biospecimens rapidly from the operating
room to the laboratory, these models offer an opportunity to assess
putative therapeutic agents while preserving essential patient tumor
characteristics. Such an approach was recently reported by our group
and others identifying PIK3CA mutation as a predictive biomarker to
Phosphoinositol-3-kinase (PI3K) pathway inhibitors in HNSCC
[10,35]. Although the predictive biomarkers of response to JAK1/2
inhibitors including AZD1480 remain unknown, our results in PDX
models may reflect different clinical responses of patients to agents in
the clinic.
Cumulative evidence supports activation of STAT3 as an
oncogenic pathway in many cancers including both solid tumors
and hematopoietic malignancies. In the absence of a STAT3 selective
targeting agent amenable to systemic administration, small molecule
JAK inhibitors represent a plausible clinical strategy to abrogate
STAT3 signaling. In the present study, we tested the effects of
AZD1480, an orally active pharmacologic inhibitor of JAK1/JAK2,
in preclinical HNSCC models including immortalized cell lines.
AZD1480 was also tested in PDX models derived from primary
HNSCC tumors. Our results suggest that JAK inhibition abrogates
STAT3 activation with heterogeneous responses in both cell lines and
animal models. Further evaluation of pJAK1/pJAK2 levels in the
HNSCC patient tumors used for heterotopic tumorgraft demon-
strated increased expression of pJAK2 in the PDX that was more
sensitive to AZD1480 suggesting that baseline pJAK2 expression may
contribute to mediating responses to JAK inhibitors.
Conclusion
Our studies suggest that the STAT3 protein can be targeted using
AZD1480, the JAK1/2 inhibitor. AZD1480 is able to inhibit
proliferation of the HNSCC cell lines, downmodulate pSTAT3
in vitro in a dose-dependent manner, as well as reduce tumor growth
in HNSCC PDX models in conjunction with decrease in pSTAT3
expression in the PDX tumors.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.01.003.
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